HanchorBio dedicates to develop biological medicines with simultaneous multi-targeting through a novel IgG Fc-Based Designer Biologics (FBDB™) platform.
CULTURE
The culture of emphasis on innovation, quality, and speed will remain and be nourished
VISION
To be a pioneering biotech company that transforms innovative drug development with biologics having novel modalities.
MISSION
MISSION To transcend the Immuno-Oncology therapeutics by developing cutting-edge designer biologics with innovative modalities for cancer patients.
CORE VALUES
INNOVATION
INTEGRITY
EXECUTION
EXCELLENCE
ACCOUNTABILITY
TEAM WORK
LEADERSHIP TEAM
SCOTT LIU, PH.D.
Founder, Chairman & CEO of HanchorBioFounder, Chairman & CEO of HanchorBio
SCOTT LIU, PH.D.
- Co-Founder and ex-CEO of Henlius/Henlix/Hengenix, a commercial-stage biopharma. company listed on HK Stock Exchange with a valuation of ~US$3 Billion
- 12-years experience in corporate developmet & management, strategic planning, fundraising & BD,… etc.; led Henlius from a start-up biotech to a top biopharma in China, with 3 commercial mAb products lunched in China and EU
- 30-year experiences in biotech R&D, cGMP quality operation and management, CMC & clinical regulatory affairs, portfolio management etc.
- Led Henlius teams in development of >30 biosimilars, novel mAbs and bsAbs, and combo immunotherapies.
- Development of multiple biologic products from research to launch, including Orencia® (for rheumatoid arthritis), Vectibix®(for colorectal cancer), Hanlikang® (Rituxan biosimilar, for lymphoma), Hanquyou®/Zercepac® ( Herceptin biosimilar, for breast & gastric cancers), and Handayuan (Humira biosimilar for autoimmune diseases)
- Director, Quality Analytical Laboratories, Amgen (Fremont, CA) (now B.I.)
- Associate Director, Biologics QC, Bristol-Myers Squibb (Syracuse, NY)
- VP, Scientific Affairs, United Biomedical Inc. (Happauge, NY)
- Ph.D. in biology at Purdue University and postdoc at Stanford University
Yuehua Cong, Ph.D.
Chief Business OfficerChief Business Officer
Yuehua Cong, Ph.D.
- VP of Business Development for Europe/UK at Simcere Pharmaceutical Group, responsible for in-licensing and out-licensing.
- Head of Business Development at F-star Biotechnology where he completed several major licensing agreements.
- Head of Business Development & Scientific Liaison and Head of Chemistry Department at PolyTherics Ltd.
- Dr. Cong has extensive business development and investment experience in life sciences; is proficient in applying international partnership models with excellent track records of in-licensing and out-licensing; has entrepreneurial experience in company building; possesses multidisciplinary scientific background coupled with visionary leadership and teamwork abilities.
- PhD in Organic Chemistry, University of Konstanz, Germany
- MSc in Environmental Quality and Safety, University of Magdeburg, Germany
- MEng in Chemical Engineering, Northeastern University, China